There is increasing evidence that liquid biopsy has the potential to change the clinical management of lung cancer.
This transformative future for patient care will be the focus of the WCLC 2022 education session “Role of Novel Biomarkers and Technologies in Optimal Diagnosis and Disease Management: Focus on Liquid Biopsies and Advanced Tissue Diagnostics” at 14:30 CEST on Tuesday, August 9, in Hall C8. Presentations will be followed by a Q&A, and a recording of the session will be available on-demand via the conference’s virtual platform within 24 hours.
“Liquid biopsy and, in particular the analysis of circulating tumor DNA (ctDNA) has dramatically changed the scenario of lung cancer research,” said session co-moderator Umberto Malapelle, PhD, chief supervisor of the Predictive Molecular Pathology Laboratory at the University of Naples Federico II in Naples, Italy. “In order to make it possible to transfer this fascinating tool from clinical trials to clinical practice, education is a crucial step.”
This education will have to start with preanalytical management of blood samples and other biofluids and extend to result interpretation from the clinical point of view, Dr. Malapelle said.
Role of Novel Biomarkers and Technologies in Optimal Diagnosis and Disease Management: Focus on Liquid Biopsies and Advanced Tissue Diagnostics
- Time: 14:30 – 15:30 CEST
- Date: Tuesday, August 9
- Location: Hall C8
- Moderators: Umberto Malapelle, PhD, and Christian Diego Rolfo, MD, PhD, MBA
A thorough understanding of liquid biopsy could allow for the implementation of this technology in different settings, not only in the metastatic disease setting to assess the presence of actionable mutations, but also to monitor minimal residual disease and to intercept the emergence of new resistance mechanisms.
“By attending this session, attendees can share knowledge with the speakers and colleagues, and allow networking among different laboratories and institutions from a variety of countries,” Dr. Malapelle said. “This represents one of the best ways to improve knowledge regarding the application of liquid biopsies and advanced tissue diagnostics.”
Speakers at the session will touch on a variety of topics including application of next-generation technologies, the use of circulating free nucleic acids, and tissue-based biomarker profiling to support clinical decision making in patients with lung cancer.
Dr. Malapelle will be joined by session co-moderator Christian Diego Rolfo, MD, PhD, MBA, of the Icahn School of Medicine at Mount Sinai in New York City, and three other presenters.
The session will include four presentations:
- “Advances and Role of CTCs for Lung Cancer Diagnosis and Treatment (Early and Advanced: NSCLC and SCLC)” presented by Caroline Dive, PhD, CBE, FMedSci
- “Optimal Use of ctDNA Analysis Lung Cancer Diagnosis, Response Assessment and Monitoring” presented by Dr. Rolfo
- “Biomarker Analysis of the Tumor Microenvironment and Tumor-Immune Cell Interactions Using High-Plex Spatial and Single-Cell Studies” presented by Junko Tanizaki, MD, PhD
- “Advanced Tumor-Based and Circulating Diagnostics in Early-Stage Disease” presented by Lillian Siu, MD
